Suita, Japan

Yasutake Tanaka

This inventor holds 1 USPTO granted patent. Top assignees: Kabushiki Kaisha Yakult Honsha, National Cerebral and Cardiovascular Center. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yasutake Tanaka. Retrieved from https://idiyas.com/inventor/yasutake-tanaka-4a6p6nhc

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yasutake Tanaka: Innovator in Tumor Immunotherapy

Introduction

Yasutake Tanaka is a notable inventor based in Suita, Japan. He has made significant contributions to the field of tumor immunotherapy, particularly through his innovative patent that enhances immune response.

Latest Patents

Tanaka holds a patent for an "Antitumor effect potentiator." This invention serves as an activator suitable for immune response in tumor immunotherapy using an immune checkpoint inhibitor. The agent is designed to potentiate the antitumor effect of an immune checkpoint inhibitor and may include probiotics and prebiotics as active ingredients.

Career Highlights

Throughout his career, Tanaka has worked with prominent organizations, including Yakult Honsha Co., Ltd. and the National Cerebral and Cardiovascular Center. His work in these institutions has allowed him to focus on advancing medical research and developing innovative solutions for cancer treatment.

Collaborations

Tanaka has collaborated with esteemed colleagues such as Takashi Asahara and Takahito Miura. Their combined expertise has contributed to the development of groundbreaking therapies in the field of immunotherapy.

Conclusion

Yasutake Tanaka's contributions to tumor immunotherapy through his innovative patent highlight his role as a key figure in medical research. His work continues to inspire advancements in cancer treatment and immune response enhancement.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…